Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Ocugen Diversifies Its Pipeline With New Cell Therapy Platform

  • Ocugen Inc (NASDAQ:OCGN) says it is diversifying its pipeline by introducing a Phase 3 cell therapy platform technology called NeoCart (autologous chondrocyte-derived neocartilage). 
  • Recently, the FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart to repair full-thickness lesions of the knee cartilage in adults.
  • NeoCart is a three-dimensional tissue-engineered disc of new cartilage manufactured by growing chondrocytes – the cells responsible for maintaining cartilage health – derived from the patient on a unique scaffold. 
  • Also See: FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial.
  • NeoCart has the potential to accelerate healing and reduce pain by rebuilding a patient's damaged knee cartilage. It treats pain at the source, creating a similar, functional joint surface as it was before the injury. Ultimately, the goal is to prevent a patient's progression to osteoarthritis. 
  • NeoCart was acquired as a part of Ocugen's reverse merger with the original developer of the therapy, Histogenics, in 2019.
  • Details of the NeoCart development program will be shared at a future date.
  • Price Action: OCGN shares are up 0.91% at $2.21 during the premarket session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.